In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum ...
Pharma Funding Roundup: QuantX Biosciences, Pandorum Technologies Complete Series B Financing Rounds
In a separate financing round, Pandorum Technologies announced the close of an $18 million Series B financing to support the ...
Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory ...
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, ...
The EY deals leader discusses recent findings and trends from 2025.
Iambic’s AI-platform includes Enchant, a multimodal transformer model designed to predict both preclinical and clinical endpoints, alongside NeuralPLexer. 1 Enchant recently received Nvidia HGX B200 ...
Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the ...
Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.
Novo Nordisk, the manufacturer of Wegovy, responded strongly to the initial launch of Hims & Hers’ compounded semaglutide ...
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate ...
Real-world data (RWD) is transforming clinical research, augmenting existing randomized controlled trial (RCT) data to de-risk studies and improve generalizability. With regulators setting clearer ...
Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results